provides increased access to compounded tirzepatide and semaglutide, perfectly timed to support Americans pursuing their 2026 health and wellness resolutions. As millions of Americans set ambitious weight loss goals for the new year, CoreAge Rx's...
retailing for $219.99. The product will also be available for purchase in select Target stores beginning February 16, 2026. The pump will be available through DME (Durable Medical Equipment) providers as an upgrade option. For more information...
in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will be based at the company’s new global...
syringe (PFS). The PFS presentation is expected to be available on the European market starting in the second quarter of 2026. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to...
neuromodulation. Nia Therapeutics is preparing for first-in-human studies, with regulatory submissions planned for 2026. The initial study will focus on patients with memory loss resulting from moderate-to-severe traumatic brain injury. About Nia...
supporting weight loss in people living with obesity. We are really looking forward to the commercial launch of MOVIVA® in 2026,” says Marcus Felstead, Chief Commercial Officer at Erbe Elektromedizin. Register for the free webinar "Advancing...
referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major...
monitoring. KYZATREX will be available through multiple telehealth and traditional provider options in the first half of 2026.The availability of an oral testosterone option presents a convenient alternative to injectable or transdermal...
of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to...
candidate RLS-1496 in patients with actinic keratosis. The Gulf Cooperation Council (GCC) study is expected to begin in Q2 2026. “In our earliest meetings with the Hevolution team, we were convinced that Saudi Arabia and the GCC had the potential...
from development to delivery. The 20,000-square-foot expansion, which began in Q4 2025 and is expected to be finalized in 2026, will significantly strengthen Alcami's analytical capabilities in support of biologics, peptides, oligonucleotides,...
of CTx001. The trial will enrol patients across leading retinal centres with first patient dosing expected in the US in Q1 2026. The trial design is informed by data from i-GAIN, a natural history study involving over 230 participants, which has...
Waldencast plans to launch Obagi® saypha® MagIQ™ in the U.S. market alongside other important skin care innovations in 2026. This launch will leverage Obagi Medical’s established network of practices and aesthetic professionals, creating synergies...
potential in this patient population." The Company expects to report topline data from the Phase 3 CYPRESS trial in Q1 2026. In parallel, Theravance is preparing for an expedited NDA submission following the results and is planning to request...
restoring agency to patients." The platform is currently available in 25 states with plans to serve all 50 states by 2026. Patients can access the platform at crafttelemed.com with transparent, pay-per-prescription pricing and no subscription fees....
This is a major step forward for European biotech leadership in space." The first joint mission is targeted for launch in 2026. Exobiosphere will contribute its autonomous screening payload, capable of executing over 2,000 cellular assays per...
per year with routinely >96% success rate and is expected to multiply the output of patient-derived iPSC-derived cells by 2026. “Numerous conversations with our clients reveal that relevant human cell models are not readily available, often...
such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position...
are in final lead selection studies and manufacturing, in parallel, to prepare for the first-in-human study planned for 2026. "Our Phase 1 data for XmAb942 validate our design goals for a best-in-class anti-TL1A therapy, combining high potency with...
as an investor and board member, it’s an honor to step into the role of CEO as we prepare to enter clinical development in 2026 for our lead neuromuscular disease candidate which we plan to announce later this year. Creyon is committed to advancing...
